Cetuximab and Irinotecan With or Without Bevacizumab in Refractory Metastatic Colorectal Cancer: BOND-3, an ACCRU Network Randomized Clinical Trial

Cetuximab and Irinotecan With or Without Bevacizumab in Refractory Metastatic Colorectal Cancer: BOND-3, an ACCRU Network Randomized Clinical Trial

BACKGROUND: Combination irinotecan and cetuximab is approved for irinotecan-refractory metastatic colorectal cancer (mCRC). It is unknown if adding bevacizumab improves outcomes. PATIENTS AND METHODS: In this multicenter, randomized, double-blind, placebo-controlled phase II trial, patients with iri...

Full description

Bibliographic Details
Main Authors: Bekaii-Saab, T. (Author), Dakhil, S.R (Author), Faggen, M. (Author), Fuchs, C.S (Author), Heying, E.N (Author), Lipsyc-Sharf, M. (Author), Meyerhardt, J.A (Author), Ng, K. (Author), Noble, S. (Author), Ou, F.-S (Author), Rubinson, D.A (Author), Schrag, D. (Author), Schuetz, S.R (Author), Stella, P.J (Author), Weckstein, D.J (Author), Wender, D.B (Author), Yurgelun, M.B (Author), Zemla, T.J (Author)
Format: Article
Language:English
Published: NLM (Medline) 2022
Subjects:
antineoplastic agent
Antineoplastic Combined Chemotherapy Protocols
bevacizumab
Bevacizumab
camptothecin
Camptothecin
cetuximab
Cetuximab
clinical trial
colorectal neoplasm
Colorectal Neoplasms
colorectal tumor
controlled study
fluorouracil
Fluorouracil
human
Humans
irinotecan
Irinotecan
multicenter study
pathology
phase 2 clinical trial
randomized controlled trial
Online Access:View Fulltext in Publisher

Internet

View Fulltext in Publisher

Similar Items